We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+28.34%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$15.2B
AUM Growth
+$1.87B
Cap. Flow
+$90.5M
Cap. Flow %
0.6%
Top 10 Hldgs %
84.66%
Holding
125
New
12
Increased
14
Reduced
21
Closed
27

Top Buys

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$50.5M
2
AMRN
Amarin Corp
AMRN
+$43.1M
3
INSM icon
Insmed
INSM
+$26M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$19M
5
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$10.8M

Top Sells

Rank Stock Value
1
BLUE
bluebird bio
BLUE
+$22.4M
2
PHXM
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
+$20.8M
3
HALO icon
Halozyme
HALO
+$14.6M
4
EXEL icon
Exelixis
EXEL
+$11M
5
XNCR icon
Xencor
XNCR
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 99.42%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGEN
1
DELISTED
Seagen Inc. Common Stock
SGEN
$3.94B 25.93%
51,046,060
– –
INCY icon
2
Incyte
INCY
$25.9B
$2.37B 15.59%
34,251,309
+275
+0% +$18.9K
ONC
3
BeOne Medicines Ltd
ONC
$42.4B
$2.06B 13.57%
11,959,824
– –
ALXN
4
DELISTED
Alexion Pharmaceuticals
ALXN
$1.19B 7.83%
8,555,894
– –
GHDX
5
DELISTED
Genomic Health, Inc.
GHDX
$968M 6.38%
13,790,970
+396
+0% +$23.2K
BMRN icon
6
BioMarin Pharmaceuticals
BMRN
$12.9B
$735M 4.84%
7,583,084
– –
ACAD icon
7
Acadia Pharmaceuticals
ACAD
$5.08B
$590M 3.89%
28,439,114
+1,210,776
+4% +$19M
AMRN
8
Amarin Corp
AMRN
$298M
$554M 3.65%
1,703,475
+570,000
+50% +$43.1M
MDGL icon
9
Madrigal Pharmaceuticals
MDGL
$11.9B
$250M 1.65%
1,169,278
– –
ASND icon
10
Ascendis Pharma A/S
ASND
$16.6B
$201M 1.32%
2,837,352
– –
HRTX icon
11
Heron Therapeutics
HRTX
$60.4M
$159M 1.05%
5,025,298
– –
NVTA
12
DELISTED
Invitae Corporation
NVTA
$141M 0.93%
8,399,411
– –
DBVT
13
DBV Technologies
DBVT
$914M
$124M 0.82%
550,956
– –
MRTX
14
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$118M 0.78%
2,513,462
– –
NBIX icon
15
Neurocrine Biosciences
NBIX
$15.5B
$116M 0.77%
944,624
– –
BCRX icon
16
BioCryst Pharmaceuticals
BCRX
$2.44B
$115M 0.76%
15,103,081
+1,090,909
+8% +$7.33M
ARRY
17
DELISTED
Array Biopharma Inc
ARRY
$86M 0.57%
5,656,196
– –
SAGE
18
DELISTED
Sage Therapeutics
SAGE
$80.2M 0.53%
567,497
-45,803
-7% -$7.07M
RYTM icon
19
Rhythm Pharmaceuticals
RYTM
$7.57B
$79M 0.52%
2,708,200
– –
CERS icon
20
Cerus
CERS
$566M
$77.5M 0.51%
10,749,937
– –
ARGX icon
21
argenx
ARGX
$65B
$77.3M 0.51%
1,019,557
+57,803
+6% +$5.12M
KNSA icon
22
Kiniksa Pharmaceuticals
KNSA
$6.17B
$76.5M 0.5%
3,000,000
– –
ONCE
23
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$75.5M 0.5%
1,384,130
– –
GWPH
24
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$68.5M 0.45%
396,700
+74,900
+23% +$10.8M
CBAY
25
DELISTED
Cymabay Therapeutics
CBAY
$54.5M 0.36%
4,917,700
– –
1
2 3 4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q3 2018 Portfolio in Review

As of Q3 2018, Julian Baker held 125 positions worth $15.2B, up 14% from $13.3B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Julian Baker's Q3 2018 filing shows 12 new, 14 increased, 21 reduced and 27 closed positions. Its largest new stake was Principia Biopharma Inc. Common Stock: 1,787,807 shares worth $52.2M. The largest sale was bluebird bio, an estimated $22.4M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Technology.

  • Julian Baker's largest Q3 2018 buy was Principia Biopharma Inc. Common Stock: 1,787,807 shares worth $52.2M.
  • Julian Baker added most to Amarin Corp in Q3 2018, an estimated $43.1M increase.
  • Julian Baker's biggest Q3 2018 reduction was bluebird bio, cutting an estimated $22.4M.
  • Julian Baker fully exited Exelixis in Q3 2018, selling an estimated $11M.
  • Julian Baker's ten largest holdings make up 85% of its $15.2B portfolio in Q3 2018.
  • Julian Baker opened 12 new positions and closed 27 in Q3 2018.
  • Julian Baker's portfolio value rose 14% quarter-over-quarter to $15.2B.

Based on Baker Bros. Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.